Statin-fibrate combination therapy for hyperlipidaemia: a review

  title={Statin-fibrate combination therapy for hyperlipidaemia: a review},
  author={Anthony S. Wierzbicki and Dr. D. P. Mikhailidis and Richard Wray and Michael Schachter and Robert Cramb and William Simpson and Claire Byrne},
  journal={Current Medical Research and Opinion},
  pages={155 - 168}
SUMMARY Statins and fibrates are well-established treatments for hyperlipidaemias and the prevention of vascular events. However, fibrate + statin therapy has been restricted following early reports of rhabdomyolysis that mainly involved gemfibrozil, originally with lovastatin, and recently, with cerivastatin. Despite this limitation, several reports describing combination therapy have been published. This review considers these studies and the relevant indications and contraindications. Statin… 

Statin-fibrat kombinasyon tedavisi

The role of combined statin-fibrate therapy in dyslipidemia, their mechanisms of action, efficacy and safety, and precautions needed to be taken to reduce side effects are reviewed in the light of literature.

Evaluation of a New Formulation of Fenofibric Acid, ABT-335,Co-Administered with Statins

This is the largest phase III randomized, controlled clinical programme to date evaluating the efficacy and safety of the combined use of a new formulation of fenofibric acid with three commonly prescribed statins in patients with mixed dyslipidaemia.

Statin–fibrate combination therapy is safe and effective in normalizing lipid profile and in keeping cardiovascular event rates low

Improved outcomes with combination therapy were related to younger age, no previous CVD and improvements in non-HDL-C and TG levels, and statin–fibrate combinations should still be considered in appropriate patients and not be neglected based on misinterpretation of the current evidence base.

Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe

For patients who do not reach their cholesterol goal with a statin, adding ezetimibe 10 mg significantly reduces LDL‐C compared with statin monotherapy, and this treatment option may help patients reach the new ‘stricter’ cholesterol goals.

Fibrates: Risk Benefits and Role in Treating Dyslipidemias

Fibrates have an important role in individualized approaches to management of patients at high risk of cardiovascular disease with mixed dyslipidemia and while the overall risk reduction may be moderate compared to statin therapy, a substantially greater magnitude of benefit may exist in this subset of patients.

Fibrates: where are we now?

Combination fibrates, statins, and combined therapy can be more effective in achieving optimal lipid levels than just fibrate or statin therapy alone without significant side effects as long as gemfibrozil is not used in therapy.

Review: Fibrates: therapeutic review

Clinical evidence has demonstrated the value of fibrate therapy in secondary and primary prevention settings, as well as in patients with type 2 diabetes, however, FIELD, the largest fibrates study to date in diabetic patients, showed a non-s...

Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients

Fenofibrate + simvastatin association improved lipid parameters, prothrombotic and inflammatory factors, and appeared to have a good tolerability profile over 12 months of therapy.

Fibrates: therapeutic review

The interesting results of fenofibrate on attenuation of microangiographic symptomatology potentially suggest a new recommendation for fibrate therapy, although further studies are required to validate these findings.

Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing

  • M. Farnier
  • Biology, Medicine
    Vascular health and risk management
  • 2008
Fenofibrate exerts a favorable effect on the atherogenic lipid profile of mixed dyslipidemia and can effectively reduce cardiovascular disease in patients with mixed dysipidemia.



Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia.

The combination of bezafibrate and simvastatin was more effective in controlling mixed hyperlipidaemia than either drug alone and did not provoke more adverse events.

Efficacy and tolerability of fluvastatin and bezafibrate in patients with hyperlipidemia and persistently high triglyceride levels.

In patients with persistent hypertriglyceridemia, combination therapy with fluvastatin and bezafibrate may be safely used to lower triglyceride and cholesterol levels more efficiently.

Pharmacotherapy of hypercholesterolaemia: statins in clinical practice

The objective of this article is to evaluate the roles of the lipid-lowering class of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) in reducing cardiovascular events

Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolaemia in patients with coronary artery disease.

Statin-fibrate combination treatment for up to 3 years in a cohort of patients with coronary artery disease was not associated with serious disturbances in biochemical markers of muscle or liver function.

Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia

The combination of atorvastatin with micronised fenofibrate in patients with severe mixed dyslipidemia may have a favourable effect on some major coronary artery disease risk factors.

Clinical Pharmacokinetics of Fibric Acid Derivatives (Fibrates)

Clinically, this class of drugs appears to be most useful in lipoprotein disorders characterised by elevations of very low density lipop protein and plasma triglycerides, which are often accompanied by reductions in high densitylipoprotein (HDL) levels.

Drug Treatment of Combined Hyperlipidemia

The therapeutic approach to combined hyperlipidemia involves determination of whether the cause is hepatocyte damage or metabolic derangements, and the various drugs including fibric acid derivatives, hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, and nicotinic acid which can be used either as monotherapy or in combination to manage it and to improve prognosis.